Ulixertinib hydrochloride

盐酸乌利塞替尼

Ulixertinib hydrochloride

U655979-1ml

1ml

10mM in DMSO

干燥,-80℃储存

超低温冰袋运输

Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC 50 of In Vitro Combined Ulixertinib (BVD-523; 10, 20, 30 μM; 48 hours) and VS-5584 treatment causes significant induction of cell death in human pancreatic cancer (HPAC) cells in PDAC cell lines BxPC-3, MIAPaCa-2, and CFPAC-1. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

盐酸乌利昔替尼（BVD-523 盐酸盐）是一种强效、口服活性、高选择性、ATP 竞争性和可逆的 ERK1/2 激酶共价抑制剂，对 ERK2 的 IC 50 小于 0.3 nM。盐酸乌利克替尼可抑制ERK1/2激酶的磷酸化。

1956366-10-1(DMSO)

C21H23Cl3N4O2

469.8 g/mol

CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)Cl.Cl